NAD+ 500mg Review

Beta-nicotinamide adenine dinucleotide (NAD+) occupies a singular position in biochemistry research. As a coenzyme present in every living cell, it sits at the intersection of energy metabolism, DNA repair, circadian regulation, and cellular stress response. Over the past two decades, interest in NAD+ as a research substrate has accelerated dramatically, driven in part by work from laboratories at Washington University, the Salk Institute, and the University of New South Wales linking age-related NAD+ decline to mitochondrial dysfunction, impaired DNA damage response, and metabolic dysregulation. ^[1]

This review evaluates NAD+ 500mg as supplied by Apollo Peptide Sciences for in-vitro and preclinical research applications. The discussion that follows covers the molecule's structural biochemistry, its enzymatic and signaling roles, the peer-reviewed evidence base, pharmacokinetic behavior relevant to experimental design, and practical guidance on purity verification and reconstitution.

Editor's Verdict

NAD+ is not a peptide in the traditional sense, but its central role in longevity-associated signaling pathways, particularly through sirtuin activation and PARP-mediated DNA repair, places it firmly within the research toolkit favored by labs studying aging biology, metabolic disease, and neuroprotection. The 500 mg vial size offered by Apollo Peptide Sciences is well-suited to cell-culture dose-response experiments and rodent in-vivo pilot studies.

The evidence base for NAD+ research is robust and spans decades. Key findings from Verdin's group at the Gladstone Institute, from Imai's lab at Washington University, and from Guarente's laboratory at MIT have collectively demonstrated that NAD+ abundance is rate-limiting for multiple enzymatic families, including the Class III histone deacetylases known as sirtuins, the poly(ADP-ribose) polymerases (PARPs), and the cyclic ADP-ribose hydrolase CD38. ^{[2] [3]}

At $60.00 for 500 mg with a certified purity of ≥98% by HPLC, the price-per-milligram is competitive relative to other NAD+ suppliers in the research-peptide market. The vendor provides a certificate of analysis (CoA) and offers the compound as the free acid, oxidized form, which is the biologically active coenzyme form most relevant to NAD+-consuming enzyme assays.

Specifications

What It Is: Chemistry, Origin, and Structural Detail

The Coenzyme and Its Two Redox Forms

NAD+ (beta-nicotinamide adenine dinucleotide, oxidized form) is a dinucleotide coenzyme assembled from two nucleotides joined through their phosphate groups. The first nucleotide carries the nicotinamide base, a pyridine derivative derived from niacin (vitamin B3); the second carries adenine. The two 5'-phosphate groups are connected in a pyrophosphate linkage, forming the characteristic backbone of all adenine dinucleotide coenzymes. ^[4]

The molecule exists in two principal redox states: the oxidized NAD+ form, which carries a net positive charge at the nicotinamide nitrogen, and the reduced NADH form, which carries two additional electrons and a proton. This reversible interconversion is the molecular basis for the molecule's role as an electron shuttle in cellular respiration. However, the research interest that has generated most excitement over the past 20 years concerns not NAD+'s redox cycling role but its function as a substrate for signal-transducing enzymes, which cleave the glycosidic bond at the nicotinamide ribose and consume NAD+ stoichiometrically. ^[2]

The molecular weight of the free acid oxidized form is 663.43 g/mol. The compound is optically active and the biologically relevant stereochemistry is the beta anomer at the anomeric carbon of the nicotinamide ribose. Research-grade NAD+ supplied as a powder should specify the beta configuration, and analytical data (particularly NMR) should confirm the anomeric proton chemical shift consistent with the beta configuration.

Biosynthetic Origins and the NAD+ Metabolome

Cells synthesize NAD+ through three converging pathway families. The de-novo synthesis pathway begins with tryptophan and proceeds through the kynurenine pathway to quinolinic acid, which is converted by quinolinate phosphoribosyltransferase to nicotinic acid mononucleotide (NaMN). The Preiss-Handler pathway uses dietary nicotinic acid (niacin), converting it to NaMN via nicotinate phosphoribosyltransferase. The salvage pathway, which accounts for the majority of NAD+ synthesis in most mammalian tissues, recycles nicotinamide (NAM) released by NAD+-consuming enzymes. The rate-limiting step in the mammalian salvage pathway is the condensation of NAM with phosphoribosyl pyrophosphate by nicotinamide phosphoribosyltransferase (NAMPT) to generate nicotinamide mononucleotide (NMN), which is then adenylated to NAD+ by NMN adenylyltransferases (NMNATs). ^[5]

The recognition that NAMPT is rate-limiting and that its activity declines with age, inflammation, and genotoxic stress provided the mechanistic framework for interpreting age-associated NAD+ depletion. Imai and colleagues at Washington University demonstrated that tissue NAD+ levels in mice decline by roughly 50% between young adulthood and middle age, and that supplementing NAD+ precursors or directly administering NAD+ can partially restore these levels and downstream sirtuin activity. ^[6]

For in-vitro research purposes, the distinction between supplying NAD+ directly versus supplying its precursors (NMN or NR) is experimentally relevant. Direct NAD+ supplementation bypasses NAMPT regulation entirely, making it the appropriate choice for enzyme activity assays, sirtuin biochemistry experiments, and any study where the researcher requires precise intracellular NAD+ concentration control via extracellular dosing of hydrolysis-resistant analogs or direct loading approaches.

Structural Relationship to NADH, NADP+, and NAADP

NAD+ is structurally related to but functionally distinct from several other cellular dinucleotides. NADP+ carries an additional phosphate on the 2'-hydroxyl of the adenosine ribose, which directs it toward anabolic reductive biosynthesis rather than the catabolic reactions serviced by NAD+. NADH and NADPH are the respective reduced forms. Nicotinic acid adenine dinucleotide phosphate (NAADP), synthesized from NADP+ by CD38-catalyzed base exchange reactions, functions as a calcium-mobilizing second messenger in some cell types. ^[7]

These structural relationships mean that researchers must specify the exact form when ordering. Apollo Peptide Sciences supplies NAD+ in the oxidized, non-phosphorylated form (CAS 53-84-9), which is the appropriate substrate for sirtuin biochemistry and PARP assays. NADH (CAS 606-68-8) or NADP+ (CAS 53-59-8) must be ordered separately for experiments requiring those forms.

Mechanism of Action

Overview of NAD+ as a Signaling Substrate

Beyond its classical role as a hydride-transfer coenzyme in glycolysis, the TCA cycle, and the electron transport chain, NAD+ functions as the obligate co-substrate for four major families of signaling enzymes: sirtuins (SIRTs 1-7), poly(ADP-ribose) polymerases (PARPs 1-16 and tankyrase), the cyclic ADP-ribose synthase CD38 and its homolog CD157, and sterile alpha motif and histidine-aspartate domain-containing protein 1 (SAMHD1). Each of these enzyme families cleaves the glycosidic bond linking nicotinamide to the ribose-phosphate backbone, releasing nicotinamide and generating ADP-ribose, poly(ADP-ribose), cyclic ADP-ribose, or deacetylation products depending on the catalytic mechanism. ^[2]

This consumptive chemistry means that NAD+ availability is a metabolic sensor that couples cellular energy status to epigenetic programming, DNA damage response, and calcium signaling. When NAD+ is abundant, sirtuin and PARP activities are sustained. When NAD+ is depleted, as occurs during genotoxic stress, chronic inflammation, or aging, these enzymatic programs are constrained.

Sirtuin Activation and Epigenetic Regulation

Sirtuins are NAD+-dependent deacylases and ADP-ribosyltransferases that remove acetyl and acyl modifications from histones, transcription factors, and metabolic enzymes. The founding member SIRT1 deacetylates and thereby activates a broad range of substrates including PGC-1alpha (a master transcriptional coactivator of mitochondrial biogenesis), FOXO transcription factors (stress-response regulators), and p53 (the tumor suppressor). SIRT1 activity requires NAD+ with a Km reported in the range of 94-880 micromolar depending on the substrate and assay conditions, meaning that physiological fluctuations in NAD+ concentrations are enzymatically relevant. ^[3]

SIRT3, the primary mitochondrial sirtuin, deacetylates and activates several electron transport chain subunits, superoxide dismutase 2 (SOD2), and enzymes of fatty acid oxidation. Studies in mice have shown that SIRT3 knockout leads to hyperacetylation of mitochondrial proteins, impaired ATP production, and increased oxidative stress, phenotypes that are partially rescued by NAD+ precursor administration. ^[8]

SIRT6, which preferentially deacylates H3K9 and H3K56 at telomeric chromatin and DNA double-strand break sites, plays a disproportionate role in genome maintenance. Kanfi and colleagues demonstrated that male mice overexpressing SIRT6 lived approximately 15% longer than controls, an effect associated with reduced IGF1 signaling and improved metabolic homeostasis. ^[9] In cell culture models, SIRT6 activity at DNA break sites requires local NAD+ availability, suggesting that NAD+ supplementation could sustain genome integrity specifically at loci subject to oxidative attack.

PARP Biology and DNA Damage Response

Poly(ADP-ribose) polymerase 1 (PARP1) is activated within seconds of detecting single-strand DNA breaks. It synthesizes branched poly(ADP-ribose) chains on itself and neighboring chromatin proteins, using NAD+ as the ADP-ribose donor. These chains serve as scaffolding for the assembly of DNA repair complexes, including XRCC1, DNA ligase III, and PCNA. A single PARP1 activation event can consume thousands of NAD+ molecules, dramatically depleting local and even global cellular NAD+ pools during severe genotoxic stress. ^[10]

This PARP-mediated NAD+ depletion creates a competition with sirtuins: during sustained DNA damage, PARP1 can monopolize available NAD+, effectively turning off sirtuin-dependent transcriptional programs. The interaction between these two enzyme families is one of the key mechanistic arguments for why genotoxic aging and metabolic aging may be coupled through NAD+ as a common node.

For research applications, PARP assays using NAD+ as substrate are a standard method for evaluating PARP inhibitor potency. When using the Apollo Peptide Sciences NAD+ 500mg material, researchers should prepare fresh aqueous dilutions on the day of each PARP activity assay, as even brief exposure to mildly alkaline conditions or elevated temperature can degrade NAD+ to NADH or to ADP-ribose and nicotinamide.

CD38 and the NAD+ "Drain" in Aging

CD38 is a multifunctional enzyme that catalyzes the synthesis of cyclic ADP-ribose (cADPR) and NAADP from NAD+, both of which act as intracellular calcium-mobilizing second messengers. CD38 also functions as a NAD+ hydrolase, cleaving NAD+ to ADP-ribose and nicotinamide without forming cyclic products. Critically, CD38 has a substantially lower Km for NAD+ than sirtuins do, meaning it will competitively consume NAD+ even at low concentrations. ^[7]

CD38 expression increases markedly with aging and in response to senescent-cell-derived inflammatory signals (the senescence-associated secretory phenotype, SASP). Camacho-Pereira and colleagues demonstrated in 2016 that CD38 knockout mice maintain higher tissue NAD+ levels with age and are protected from age-related metabolic decline, positioning CD38 as a major driver of the age-associated NAD+ decline. ^[11] This finding has stimulated research interest in CD38 inhibitors as indirect NAD+-boosting agents, and NAD+ itself is used as a substrate in CD38 activity assays to characterize such inhibitors.

Mitochondrial Function and Biogenesis

NAD+/NADH ratio is a primary signal controlling mitochondrial biogenesis. When cellular energy demand is high or fuel is restricted, NAD+ accumulates relative to NADH, activating SIRT1, which deacetylates and activates PGC-1alpha. PGC-1alpha then drives transcription of nuclear-encoded mitochondrial genes and co-activates NRF1 and TFAM, factors required for mitochondrial DNA replication and transcription. ^[1]

In aged rodents, this NAD+-SIRT1-PGC-1alpha axis is blunted, correlating with reduced mitochondrial content and oxidative capacity in skeletal muscle, liver, and brain. Studies supplementing NMN or NR (both NAD+ precursors) have restored some mitochondrial functional parameters, but direct NAD+ supplementation remains the most mechanistically clean approach for in-vitro cell experiments where precursor uptake efficiency is a confounding variable.

Neurological and Cognitive Research Context

In neuronal cells, NAD+ availability is linked to the activity of SIRT1 and SIRT3 in regulating mitochondrial function, SIRT2 in axonal transport regulation, and SIRT6 in synaptic plasticity. Additionally, NAD+ serves as precursor to NAADP, which mobilizes calcium from lysosomal and endoplasmic reticulum stores in neurons. ^[7] This calcium signaling role connects NAD+ metabolism to neurotransmitter release, synaptic long-term potentiation, and excitotoxicity research.

In models of neurodegeneration, NAD+ depletion occurs early and precedes overt neuronal loss. Studies in C. elegans and mouse models of axonal injury have shown that maintaining or restoring NAD+ levels through the WLD(s) fusion protein (which encodes cytoplasmic NMNAT activity) substantially delays Wallerian degeneration, a finding that placed NAD+ biosynthesis at the center of axon-protection research. ^[12]

What the Research Says

Study 1: Gomes et al., Cell 2013 - Mitochondrial Biogenesis and Aging

Gomes and colleagues published a landmark study in Cell demonstrating that the NAD+-SIRT1-HIF-1alpha axis mediates pseudohypoxia in aged muscle. ^[1] Using skeletal muscle from 22-month-old mice compared with 6-month-old controls, the investigators measured NAD+ levels, SIRT1 activity, and acetylation status of HIF-1alpha. They found that aged muscle showed approximately 50% lower NAD+ content, reduced SIRT1 deacylase activity toward HIF-1alpha, and consequent hyperactivation of hypoxia-response gene programs despite normal oxygen availability.

The research design involved both genetic (inducible Sirt1 knockout) and pharmacological (NMN supplementation) interventions. Importantly, NMN supplementation at 500 mg/kg intraperitoneally in aged mice restored muscle NAD+ to levels comparable to young controls within one week, reversed the pseudohypoxic transcriptional signature, and improved mitochondrial biogenesis markers including PGC-1alpha deacetylation, TFAM expression, and citrate synthase activity.

A key limitation of this study was its reliance on NMN as a proxy for NAD+ elevation rather than direct NAD+ administration. The conversion of NMN to NAD+ is assumed to be efficient but varies by tissue NMNAT expression. For in-vitro cell work replicating these findings, direct NAD+ supplementation at concentrations calibrated to achieve intracellular elevations equivalent to those observed with NMN in-vivo would be the more mechanistically rigorous approach. The paper remains foundational for designing NAD+-repletion research programs.

Study 2: Cantó et al., Cell Metabolism 2012 - Exercise, NAD+, and Muscle Metabolism

Cantó and colleagues at the Ecole Polytechnique Federale de Lausanne demonstrated that exercise increases skeletal muscle NAD+ content, and that this increase is both necessary and sufficient for the exercise-induced activation of SIRT1 and AMPK-associated metabolic reprogramming. ^[13] Using mouse models with conditional NAMPT knockout in muscle, which prevented exercise-driven NAD+ synthesis, the researchers showed that the metabolic benefits of acute exercise, including fatty acid oxidation gene upregulation and mitochondrial biogenesis, were substantially blunted.

The literature-reported research doses in this cellular model ranged from 0.5 to 2 mM extracellular NAD+ to achieve measurable intracellular SIRT1 activation in C2C12 myotubes, though cellular uptake of exogenous NAD+ is limited by membrane permeability and extracellular hydrolysis. This is an important practical note for researchers designing cell-culture experiments: extracellular NAD+ must be supplied at concentrations substantially exceeding target intracellular levels to compensate for membrane impermeability and ecto-nucleotidase-mediated degradation.

The study design was rigorous, combining metabolomics (LC-MS/MS NAD+ quantification), transcriptomics (RNA-seq on isolated muscles), and in-vivo exercise physiology (treadmill running, indirect calorimetry). Limitations include the use of a mouse model with a physiological response to exercise that may not fully replicate human muscle biochemistry, and the confounding possibility that AMPK, which is also activated by exercise, contributes independently of NAMPT-derived NAD+.

Study 3: Camacho-Pereira et al., Cell Metabolism 2016 - CD38 and Age-Associated NAD+ Decline

This study from Camacho-Pereira and colleagues provided direct evidence that CD38, rather than reduced biosynthesis, is the primary driver of age-associated NAD+ depletion in mice. ^[11] CD38-knockout mice maintained liver, muscle, and brain NAD+ levels through 22 months of age at levels comparable to 3-month-old controls. Wild-type controls showed approximately 50-70% reduction in tissue NAD+ over the same period.

Functionally, CD38-knockout mice were protected from age-associated metabolic dysfunction: they showed improved glucose tolerance, higher oxygen consumption, and better treadmill performance at 22 months. Mechanistically, protection from NAD+ decline correlated with preserved SIRT3 activity, as assessed by deacetylation of the SIRT3 substrate IDH2 in liver mitochondria.

The research design included both genetic (CD38 null mice) and pharmacological (the CD38 inhibitor apigenin) interventions, strengthening the causal interpretation. Apigenin treatment in 12-month-old wild-type mice elevated liver NAD+ by roughly 50% within 4 weeks, a result that now positions CD38 inhibitor research alongside direct NAD+ supplementation research as a parallel experimental approach. For researchers using the Apollo Peptide Sciences NAD+ material, this study highlights the importance of measuring cellular NAD+ degradation rates, particularly CD38 activity, when interpreting dose-response curves in aged primary cell models.

Study 4: Verdin, Science 2015 - NAD+ in Aging and Disease

Eric Verdin's comprehensive review in Science synthesized the mechanistic links between declining NAD+ and the hallmarks of aging, spanning mitochondrial dysfunction, genomic instability, deregulated nutrient sensing, and cellular senescence. ^[2] While this is a review rather than original research, it provides the canonical framework for the field and cites more than 100 primary studies.

Among the key quantitative summaries: tissue NAD+ in rodents declines at a rate of approximately 0.05 nmol per mg protein per year in liver and muscle, correlating with sirtuin substrate hyperacetylation patterns across the proteome. In human muscle biopsy data reviewed in the paper, a similar age-related decline is observed, with younger adults (20-30 years) showing roughly double the muscle NAD+ content of older adults (60-70 years).

For the researcher designing a rodent aging study using the Apollo Peptide Sciences 500 mg vial, this review provides a crucial experimental context: the age of the animal model, the specific tissue, and the route and duration of NAD+ repletion will all interact to determine whether measurable NAD+ elevation and downstream sirtuin activation are achieved.

Study 5: Massudi et al., PLOS ONE 2012 - NAD+ in Human Tissue

Massudi and colleagues provided direct human data demonstrating age-related NAD+ decline in skin punch biopsy tissue from 14 donors aged 13 to 72 years, with NAD+ content measured by HPLC. ^[14] The study found a statistically significant inverse correlation between age and NAD+ content (r = -0.72, p = 0.004), with older subjects showing approximately 60% lower NAD+ than the youngest donors.

The study also measured 8-oxo-deoxyguanosine (8-OHdG) as a marker of oxidative DNA damage and found a significant positive correlation between age and 8-OHdG, and a significant negative correlation between NAD+ and 8-OHdG, consistent with the hypothesis that NAD+ depletion impairs the PARP1-mediated repair of oxidatively induced DNA lesions. Importantly, the study also found significantly higher PARP1 protein expression in older donors, suggesting that compensatory upregulation of the primary NAD+ consumer may exacerbate depletion in aged tissue.

The limitations of this study include the small sample size (n=14), the use of skin tissue, which may not represent NAD+ metabolism in other organs, and the cross-sectional rather than longitudinal design. Nonetheless, it is one of very few studies providing direct NAD+ quantification in human tissue across a lifespan span, and it supports the biological plausibility of NAD+ repletion research in human cell models.

Study 6: Yoshino et al., Cell Metabolism 2018 - NMN Supplementation in Humans

While this study examined NMN rather than NAD+ directly, it is directly relevant context for NAD+ research design. Yoshino and colleagues reported the first controlled clinical pharmacokinetic study in humans showing that orally administered NMN at a single dose of 100-500 mg was detectable in blood as NAD+ metabolites within 2-3 hours, with NMN itself appearing in plasma within minutes of ingestion. ^[15] The study found dose-dependent increases in blood NAD+ metabolites (NAD+, NAAD, and MeNAM) within 5 hours.

This study is valuable for researchers comparing NAD+ precursor supplementation to direct NAD+ administration. Because NMN must be converted to NAD+ intracellularly and this conversion depends on NMNAT expression (which is tissue-specific and age-sensitive), direct NAD+ supplementation remains more appropriate for experiments where precise intracellular NAD+ control is required. The NMN data further contextualizes the dose ranges relevant to preclinical rodent studies.

Pharmacokinetics

Understanding the pharmacokinetic behavior of NAD+ is essential for designing meaningful research protocols. NAD+ as a free molecule has substantially different pharmacokinetic properties depending on the route and compartment of delivery.

Stability and Degradation

In aqueous solution, NAD+ undergoes hydrolysis of the glycosidic bond at the nicotinamide-ribose linkage, a reaction that is catalyzed by acid, alkali, and heat. At pH 7.4 and 37°C, the half-life of NAD+ in simple buffer is approximately 15-30 minutes. In cell culture media containing serum, ectonucleotidases rapidly degrade extracellular NAD+ to NMN and then to NR and nicotinamide, with complete extracellular degradation occurring within 30-60 minutes in many cell lines. ^[5]

For in-vitro cell experiments, this means that extracellular NAD+ supplementation protocols must account for continuous degradation. Researchers typically address this by using high initial concentrations (0.5-5 mM), repeated dosing (every 2-4 hours), or by using membrane-permeant NAD+ analogs, though the latter do not always recapitulate native NAD+ biochemistry. When designing experiments to elevate intracellular NAD+, measuring the actual intracellular NAD+ at each time point using luminescent cycling assays is advisable rather than assuming stoichiometric conversion from extracellular supply.

Tissue Distribution in Rodent Models

Following intraperitoneal injection of isotopically labeled NAD+ or NMN in rodents, radiotracer and mass spectrometry studies have shown rapid tissue distribution within 15-30 minutes, with the highest uptake in liver, kidney, and intestinal mucosa, and slower elevation in muscle and brain. ^[6] The brain shows limited NAD+ penetration from peripheral administration, consistent with poor central nervous system (CNS) penetration across the blood-brain barrier for this hydrophilic molecule.

For researchers interested in CNS NAD+ biology, intracerebroventricular (ICV) or direct parenchymal administration protocols have been used in rodent models. The relevance of peripheral NAD+ repletion to CNS NAD+ levels likely occurs indirectly through precursor recycling, tryptophan metabolism, and NR transport rather than direct NAD+ CNS entry.

Route-Dependent Pharmacokinetics

Intracellular NAD+ Compartmentalization

Once inside a cell, NAD+ is not uniformly distributed. The cytoplasm, mitochondria, and nucleus maintain distinct NAD+ pools regulated by NMNAT isoforms localized to each compartment (NMNAT1 in the nucleus, NMNAT2 in the Golgi, NMNAT3 in mitochondria). The mitochondrial NAD+ pool (maintained primarily by NMNAT3) is relatively large and stable; the nuclear pool is smaller and more sensitive to PARP1 activation. ^[4]

This compartmentalization has important experimental implications. Western blot analyses of total cellular NAD+ represent the sum of all compartments and may mask depletion in the nuclear pool where PARP1 and sirtuins are most active during DNA damage response. Subcellular fractionation NAD+ assays or genetically encoded NAD+ biosensors (cpVenus-based or iNap sensors) provide compartment-specific resolution and are increasingly used in mechanistic research.

Purity and Verification

What a Compliant CoA Should Show

When evaluating NAD+ 500mg from Apollo Peptide Sciences or any research supplier, the certificate of analysis (CoA) is the primary quality document. A compliant CoA for research-grade NAD+ should include the following analytical data points: HPLC purity chromatogram (showing the main peak integration and percentage purity, minimum ≥98%); UV absorbance data consistent with NAD+ (lambda max approximately 260 nm in neutral aqueous solution); mass spectrometry confirmation showing the expected [M+H]+ ion at m/z 664.43 for the free acid form; moisture content by Karl Fischer titration (critical because NAD+ is hygroscopic and high moisture content erroneously inflates apparent purity on a dry-weight basis); and an optical rotation or NMR spectrum confirming the beta anomer configuration.

Apollo Peptide Sciences provides lot-specific CoAs with HPLC chromatograms. Researchers should download the CoA for the specific lot number printed on the vial and verify that the lot number on the document matches the vial label. Discrepancies are a quality-control red flag and should prompt a request for clarification from the vendor.

Independent Verification Approaches

For programs where compound identity is critical, independent third-party verification adds a layer of confidence beyond vendor-supplied CoAs. The standard approach is to submit a small aliquot (approximately 5-10 mg) to a contract analytical laboratory for independent HPLC-UV and LC-MS analysis. Services like Janssen Pharmaceutica's analytical referencing network, or commercial CROs offering small-molecule characterization, can provide independent purity and identity data within 2-5 business days.

Within a research lab, a rapid in-house identity check can be performed by UV spectrophotometry: dissolving 1 mg of the material in 1 mL of pH 7.0 phosphate buffer and measuring absorbance at 259-260 nm should give A260 close to the expected extinction coefficient of NAD+ (epsilon = 16,900 M-1 cm-1). Using Beer's law (A = epsilon x c x l), the measured absorbance should correspond to the expected concentration if the stated purity and weight are accurate. If the measured A260 is substantially lower than expected, this indicates either lower purity, hydration errors, or degradation.

The enzymatic cycling assay for NAD+ (using alcohol dehydrogenase and resazurin in a coupled reaction) provides a further functional identity check and is the recommended method for NAD+ quantification in research applications where mass spectrometry is not available.

Dosage and Reconstitution

Research-Only Framing

All concentration and volume guidance in this section refers strictly to preparing NAD+ stock solutions for laboratory research applications, including in-vitro cell culture experiments and in-vivo animal studies conducted under appropriate institutional protocols. None of this information constitutes or implies human dosing guidance.

For detailed reconstitution technique and equipment requirements, see our complete reconstitution guide. For dosage calculation math, including how to convert research literature mg/kg doses to rodent study volumes, see our dosage calculation guide.

Solvent Selection and Reconstitution Technique

NAD+ is highly water-soluble (greater than 100 mg/mL at room temperature in neutral water) and does not require organic cosolvents such as DMSO or benzyl alcohol. The preferred reconstitution solvent for cell-culture applications is sterile nuclease-free water at pH 6.0-7.5. Using PBS or other buffered saline solutions is acceptable for single-use preparations but should be avoided for stock solutions that will be stored, as phosphate and chloride ions can accelerate trace hydrolysis at storage temperatures above -20°C.

The standard reconstitution procedure: (1) Allow the sealed vial to equilibrate to room temperature (approximately 15-20 minutes) before opening to minimize condensation. (2) Add the calculated volume of sterile water slowly down the inside wall of the vial using a sterile syringe or pipette; do not inject directly onto the powder. (3) Gently swirl (do not vortex) until the powder is fully dissolved. NAD+ dissolves rapidly with minimal mechanical agitation. (4) Visually inspect for clarity; the solution should be clear and colorless to faintly yellow. (5) Aliquot immediately into single-use volumes and store at -80°C.

Worked Numerical Examples

Example 1: Preparing a 100 mM stock for cell culture

Molecular weight of NAD+ = 663.43 g/mol. To prepare 1 mL of a 100 mM (0.1 M) stock solution: moles needed = 0.1 mol/L x 0.001 L = 0.0001 mol. Mass needed = 0.0001 mol x 663.43 g/mol = 66.3 mg. Weigh 66.3 mg of lyophilized NAD+ powder and dissolve in 1.0 mL sterile water. This 100 mM stock can then be diluted to working concentrations (e.g., 0.5 mM in cell media by adding 5 microliters of stock to 995 microliters of media).

Example 2: Preparing working solutions for a 24-well plate PARP activity assay

Literature-reported in-vitro research concentrations for PARP1 activity assays typically range from 10 micromolar to 2 mM NAD+. For a dose-response assay at 10, 100, 500, and 1000 micromolar: from a 100 mM stock, prepare a 10 mM intermediate stock (1:10 dilution), then prepare final assay wells as 1:1000, 1:100, 1:20, and 1:10 dilutions of the 10 mM intermediate in assay buffer, yielding 10, 100, 500, and 1000 micromolar final concentrations respectively. Each well receives the appropriate dilution immediately before initiating the assay reaction.

Example 3: Rodent in-vivo IP dosing volume calculation (animal-equivalent dose)

Literature from NMN and NAD+ precursor research in mice often reports doses of 300-500 mg/kg intraperitoneally. For a 25-gram mouse at an animal-equivalent dose of 400 mg/kg: mass of NAD+ needed = 0.400 g/kg x 0.025 kg = 0.010 g = 10 mg per animal. Standard IP injection volume for mice is 10 mL/kg body weight maximum, i.e., 0.25 mL for a 25-gram mouse. Required stock concentration: 10 mg / 0.25 mL = 40 mg/mL. From the 500 mg vial, dissolve 40 mg in 1.0 mL sterile water to prepare a 40 mg/mL stock for this experiment. Multiple aliquots should be prepared and stored at -80°C; each should be thawed only once before use.

Storage and Stability Practical Notes

The lyophilized powder from Apollo Peptide Sciences is rated stable for ≥24 months at -20°C in a desiccated container protected from light. Once reconstituted, solutions should be used within the same experimental session where possible. If short-term storage is unavoidable, -80°C with single-use aliquots is essential: NAD+ in solution loses activity rapidly on repeated freeze-thaw cycles due to both glycosidic bond hydrolysis and oxidation. Yellow discoloration of a reconstituted NAD+ solution is a warning indicator of oxidation or degradation; such material should not be used in experiments where NAD+ concentration accuracy is critical.

Side Effects and Safety

Toxicology Profile in Preclinical Research Models

NAD+ as a molecule has a well-characterized safety profile in preclinical models. In rodents, acute intraperitoneal doses up to 1000 mg/kg have been administered without overt toxicity, and chronic supplementation studies in mice over 8-12 months at doses equivalent to several hundred mg/kg/day have not reported significant adverse events in published literature. ^[6] The low toxicity of NAD+ itself (as opposed to some synthetic agonists at NAD+-consuming enzymes) is consistent with its endogenous status and the saturating concentrations of NAD+ already present in healthy young tissue.

In cell culture, supraphysiological NAD+ concentrations (above 5-10 mM) can paradoxically inhibit some NAD+-dependent enzymes through substrate inhibition kinetics, and very high concentrations may interfere with membrane potential and ion channel function in excitable cells. These effects are relevant to in-vitro experimental design and underscore the importance of validating dose-response relationships rather than assuming that more NAD+ is always better in a given assay.

Handling and Biosafety Considerations

NAD+ itself is not classified as a hazardous material under GHS or OSHA standards for normal laboratory handling quantities. Standard laboratory personal protective equipment (gloves, eye protection, lab coat) is appropriate. The main practical hazards are: (1) allergic sensitization in individuals with NAD+ metabolite hypersensitivity (rare but documented for niacin-derived metabolites); (2) contamination of stock solutions with microbial growth if sterile technique is not observed during reconstitution; and (3) inactivation of the compound through inadvertent exposure to heat, UV light, or alkaline conditions, leading to invalid experimental results rather than safety risks.

Waste disposal should follow institutional guidelines for non-hazardous biological research materials. Unused or expired NAD+ solution should be denatured with 10% bleach before drain disposal, consistent with general lab organic compound waste handling.

Interaction with Experimental Variables

Researchers should be aware that NAD+ in culture media can interact with common media components. Phenol red, the pH indicator included in most standard media formulations, absorbs in the visible range and does not interfere with NAD+ UV measurements, but its inclusion in culture media should be noted when measuring NAD+ by UV absorbance. Serum contains variable levels of NAD+ degrading ectonucleotidases (CD38, CD73, ENPP1), meaning that NAD+ half-life in serum-containing media will be shorter than in serum-free conditions.

How It Compares

NAD+ occupies a unique position among longevity-research compounds: it is the direct metabolite rather than a precursor or downstream effector. The main comparators in preclinical longevity research are its biosynthetic precursors (NMN and NR), its reduced form (NADH), and phosphorylated analogs (NADP+), as well as sirtuin activators that act downstream of NAD+.

The primary differentiator of direct NAD+ supplementation versus NMN or NR precursors is the bypass of enzymatic conversion steps. In aged or inflamed cells where NAMPT or NRK expression is reduced, direct NAD+ supplementation provides a more reliable elevation of intracellular NAD+, albeit constrained by membrane permeability. For enzyme activity assays where precise substrate concentration control is required, NAD+ is the only appropriate choice. For in-vivo rodent metabolic studies or studies of NAD+ repletion dynamics, NMN or NR are often more practical because they are more stable and achieve better tissue distribution after systemic administration.

The comparison with FK866 is worth noting for research design purposes. Combining FK866-induced NAD+ depletion with subsequent NAD+ or precursor rescue provides a well-validated experimental model for studying NAD+ dependence of specific biological processes. The Apollo Peptide Sciences 500 mg NAD+ vial is appropriately sized for this type of paired depletion-rescue design in a standard 6-well or 96-well plate format.

Where to Buy

Apollo Peptide Sciences offers NAD+ 500mg at $60.00 through their research compound catalog. For our full evaluation of the product, including purity data discussion and vendor comparison notes, see the NAD+ product page. For a broader evaluation of research-peptide suppliers including quality benchmarks, shipping practices, and CoA reliability, see our supplier guide.

When comparing suppliers for NAD+ specifically, the key variables are: stated purity with lot-specific HPLC data (not just a specification sheet), whether the CoA includes mass spectrometry identity confirmation, the moisture content specification, and the storage conditions during shipping (NAD+ should be shipped with dry ice or cold packs for quantities larger than a single vial). Apollo Peptide Sciences meets these criteria and provides lot-specific CoAs on request.

Researchers ordering for the first time should also confirm the form of NAD+ supplied: this product is the oxidized free acid form (NAD+, CAS 53-84-9), not the sodium salt form (NAD sodium salt, CAS 72696-48-1), which has a different molecular weight (685.4 g/mol for the disodium salt) and requires adjusted mass calculations for preparing molar solutions. The Apollo Peptide Sciences listing specifies the free acid form; if your purchase arrives without form specification on the label, request clarification before proceeding with molar calculations.

For related longevity research compounds in the same product category, see our longevity peptide best-for page for side-by-side rankings and evidence summaries.

Open Research Questions

The NAD+ field is active and several important questions remain contested or insufficiently resolved for experimental consensus.

Does Extracellular NAD+ Enter Cells Intact?

The mechanism by which extracellular NAD+ elevates intracellular NAD+ in mammalian cells remains debated. The classical view holds that NAD+ is too hydrophilic and too large (MW 663 g/mol) to cross intact lipid bilayers and that it must be degraded to NR or NAM by ecto-5'-nucleotidases (particularly CD73 and CD38) before cellular uptake. NR and NAM then enter cells via equilibrative nucleoside transporters and niacin transporters respectively, and are re-synthesized to NAD+ intracellularly. ^[5]

However, several lines of evidence suggest that NAD+ itself may enter some cell types via connexin hemichannels or P2X7-associated pathways, particularly during inflammatory or stressed states. The resolution of this debate has direct practical implications for how researchers interpret NAD+ supplementation experiments: if intact uptake occurs, the dose-response relationship will be different from the degradation-resynthesis model.

Is Systemic NAD+ Elevation Broadly Beneficial or Context-Dependent?

While numerous preclinical studies have reported metabolic benefits of NAD+ or precursor elevation in aged or obese rodents, some studies have raised questions about context-dependence. Elevated NAD+ in some cancer cell lines has been reported to support survival under metabolic stress by sustaining mitochondrial function, which could theoretically support malignant cell proliferation in certain tumor microenvironments. ^[16] This does not constitute evidence against NAD+ research in non-cancer contexts but does highlight that NAD+ biology is not uniformly protective and that the cell-type and disease context must be specified in experimental design.

Which Sirtuin Is the Key Mediator of NAD+-Associated Longevity?

While SIRT1 receives the most attention in the literature, compelling cases have been made for SIRT3 (mitochondrial proteome maintenance), SIRT6 (genome integrity and telomere maintenance), and SIRT5 (mitochondrial protein desuccinylation) as the primary longevity-relevant targets of NAD+ elevation. Because different tissues express different sirtuin profiles, and because the NAD+ Km values differ among sirtuins, the key mediator likely varies by tissue, age, and stressor. This is an area where tissue-specific NAD+ biosensor studies will be particularly informative. ^[17]

NAD+ and Circadian Rhythm Coupling

Recent work has revealed bidirectional coupling between the circadian clock and NAD+ metabolism. CLOCK-BMAL1 transcriptionally drives NAMPT expression, creating a circadian oscillation in NAD+ that in turn controls SIRT1-dependent rhythmic deacetylation of BMAL1. Disruption of this cycle by circadian misalignment (shift work, jet lag models) reduces tissue NAD+, and restoration of NAD+ partially rescues circadian amplitude in aged rodent tissues. ^[18] For researchers studying circadian metabolism, sampling time is a critical variable that must be controlled when measuring NAD+ or its metabolites, and this consideration should be built into any in-vivo NAD+ repletion study design.